[

glaxo

]
GSK Consumer Healthcare’s brands such as Horlicks, Boost and Maltova are now part of HUL’s food and refreshments business in the nutrition category.(Reuters)

Glaxo to sell $3.9 billion stake in HUL

Hindustan Times, Mumbai | By Swaraj Singh Dhanjal
PUBLISHED ON APR 30, 2020 05:55 AM IST
The two multinational giants had announced the all-share deal worth 31,700 crore in December 2018. Bloomberg first reported on Wednesday that GSK was in discussions with its advisers on when to launch the transaction.
Government’s proposal includes incentives for plug-in and hybrid vehicles, fuel efficiency and carbon taxation.(AP Photo)
Government’s proposal includes incentives for plug-in and hybrid vehicles, fuel efficiency and carbon taxation.(AP Photo)

Govt plans to offer incentives to 324 companies including Tesla and Glaxo: Report

Bloomberg | By Shruti Srivastava
UPDATED ON JUL 27, 2020 12:43 AM IST
Under the plan, the government will create a land bank for ready-to-move-in industrial clusters, offer investment and location-based incentives and rationalize anti-dumping duties.
Glaxo has one publicly-traded subsidiary in India for its pharmaceutical business and another for its consumer health unit.(Reuters File Photo)
Glaxo has one publicly-traded subsidiary in India for its pharmaceutical business and another for its consumer health unit.(Reuters File Photo)

Glaxo may sell $3.1 billion India consumer unit stake to finance Novartis JV buyout

Bloomberg | By Ari Altstedter, Bloomberg
PUBLISHED ON MAR 27, 2018 05:32 PM IST
Proceeds from a potential sale of GlaxoSmithKline Consumer Healthcare Ltd would be used to finance Glaxo’s $13 billion buyout of Novartis AG’s stake in their consumer-health joint venture.
Glaxo pulled out of the contest for Pfizer’s consumer-health unit last week in a development that leaves the US drugmaker with dwindling options to dispose of the business, which is valued at as much as $20 billion.(REUTERS File Photo)
Glaxo pulled out of the contest for Pfizer’s consumer-health unit last week in a development that leaves the US drugmaker with dwindling options to dispose of the business, which is valued at as much as $20 billion.(REUTERS File Photo)

GSK to buy stake in Novartis consumer-health joint venture for $13 billion

James Paton, Bloomberg | By HT Correspondent
UPDATED ON MAR 27, 2018 03:07 PM IST
Glaxo’s boss has said that buying the Novartis holding, whose products include Sensodyne toothpaste, Theraflu cold medicine and Panadol pain relievers, would strengthen its consumer business.
SHARE
Story Saved